Public Policy and Human Rights
The human being at international law is collectively referred to as “humankind” encompassing all members of the human species as a whole, and it is in this context that the aviation perspective should look at the people affected by it both as a whole and in the singular context of the passenger carried by air. The Universal Declaration of Human Rights of the United Nations recognizes the inherent dignity and of the equal and inalienable rights of all members of the human family as the foundation of freedom, justice and peace in the world, and provides that everyone has the right to freedom of movement and residence within the borders of each state and everyone has the right to leave any country, including his own, and to return to his country. The Declaration also provides that everyone has the right to life, liberty and security of person, implying that such rights should not be arbitrarily taken away by any means.
Europeanization of Public Policy in International Family Law-Overriding National Values or Gradual Harmonization?
The research paper examines European public policy in cross-border family law in Europe as established by the jurisprudence of the European Court of Human Rights and the Court of Justice of the EU. The goal is to identify recent case law and to review on which family matters the European public policy has already been created, on the one hand, and for which questions the development is slower and why, on the other hand. The normative and comparative methods are predominantly used in the paper to conduct a qualitative assessment. The analysis shows that the European public policy is at an advanced stage of development on same-sex communities and family name, in an early stage of development on surrogate motherhood and non-existing on private divorces conducted under Islamic law. The reasons confirm discussions in the literature on movement from status to contract law in family law matters except for samesex communities, but also predict a slower development of the European public policy in times of the COVID-19 and economic crisis.
Antitumor activities of (2"R)-4'-O-tetrahydropyranyl-adriamycin (THP) and its combination with other antitumor agents on murine tumors.
(2''R)-4'-O-Tetrahydropyranyladriamycin (THP) is a new derivative of doxorubicin (adriamycin, ADM). The concentrations of THP and ADM required to inhibit by 50% the growth of a cultured L1210 cells was 0.003 microgram/ml and 0.016 microgram/ml, respectively. Various therapeutic designs of combinations of THP with other antitumor agents were investigated in vivo using the L1210 murine leukemia. The combination of THP with cytosine arabinoside (Ara-C), cyclocytidine hydrochloride (Cyclo-C), 6-mercaptopurine (6-MP) and cyclophosphamide (EX) showed a great effectiveness following daily intraperitoneal treatment from days 1 to 10. High therapeutic effects were also obtained with the combinations of THP with Ara-C, Cyclo-C, vincristine (VCR) and EX following intravenous combination therapy one day following implantation of L1210 leukemia. Schedule dependency and its therapeutic efficacy of THP were examined. THP showed almost the same antitumor activity on the solid-type sarcoma-180 or solid-type Ehrlich carcinoma as ADM by intraperitoneal or intravenous treatment. THP showed some superior activity to ADM in the advanced stage of L1210 leukemia. High antitumor activity of THP on murine leukemia L1210 has been reported by Tsuruo et al. (Cancer Res. 42: 1462-1467, 1982) and was also confirmed. THP gave many mice cures, especially in the intravenous treatment.